Von Eschenbach May Speed Changes In “Strategic Direction” At FDA – Galson

FDA Acting Commissioner Andrew von Eschenbach could serve as a catalyst for policy initiatives at the agency, Center for Drug Evaluation & Research Director Steve Galson said Oct. 24